News

JSR Agrees to Acquire Medical 3D Software Company Lexi Co., Ltd.

JSR Corporation (JSR) announced that it has agreed to acquire Lexi Co., Ltd. (Lexi) a medical 3D software company. Through this acquisition, JSR will establish a new business in life sciences by integrating Lexi's 3D software technology with JSR's 3D printing and materials technologies. The JSR Group is focused on creating novel value and capitalizing on the trend toward digitization in the medical and life sciences industries.

Read more about JSR Agrees to Acquire Medical 3D Software Company Lexi Co., Ltd.

JSR Life Sciences Expands Amsphere™ A3 Production Capacity

Tokyo, Japan - May 9, 2017 – JSR Life Sciences (JLS), the global life sciences focused division of JSR Corporation, today announced plans for expansion of its production capabilities of Amsphere™ A3 protein-A chromatography resin at JSR’s Belgium subsidiary, JSR Micro NV. This expansion will effectively increase its production capacity by 6 times and provide all-important redundancy in its manufacturing capability. 

Read more about JSR Life Sciences Expands Amsphere™ A3 Production Capacity

Implementation of Amsphere™ A3 in Phase II manufacturing

For several years, the JSR Life Sciences team worked closely with the LFB team at the bioproduction facility in Alès (LFB Biomanufacturing), cumulating in the implementation of the Amsphere™ A3 Protein-A media in clinical Phase II manufacturing of a monoclonal antibody. LFB recently tripled the production capacity of this facility, which also provides biomanufacturing services. The Amsphere™ A3 media offered LFB Biomanufacturing the best productivity, excellent impurity clearance and outstanding process economics in manufacturing scale.

Read more about Implementation of Amsphere™ A3 in Phase II manufacturing

Oncobiologics and JSR Life Sciences publish a poster on Trastuzumab purification

In a joint effort, Oncobiologics INC and JSR Life Sciences released a poster on the optimization of a Protein A Chromatography Process for a Herceptin® Biosimilar (Trastuzumab). Four Protein A resins from leading industry vendors, including AmsphereTM A3, were screened for use in the capture step for a Trastuzumab and multiple parameters were assessed for their performance against the platform resin.

Read more about Oncobiologics and JSR Life Sciences publish a poster on Trastuzumab purification

JSR Life Sciences Acquires Exclusive Rights to SPF Technologies’ Chromassette® Platform

JSR Life Sciences has signed a technology licensing and joint development agreement for the Chromassette® technology with SPF Technologies, LLC, a private Somerville, MA‐based company providing innovative solutions for biopharmaceutical manufacturing.

Read more about JSR Life Sciences Acquires Exclusive Rights to SPF Technologies’ Chromassette® Platform

JSR Micro, Inc. Expands JSR Life Sciences Business with MBL International, Appoints New CEO

JSR Micro, Inc. announced today that it has expanded the JSR Life Sciences business division by becoming the majority shareholder of Boston area-based MBL International Corporation (MBLI). Tim Lowery, Sr. Vice President of Emerging Technologies at JSR Micro, Inc., has been appointed as the Chief Executive Officer of MBLI effective immediately. 

Read more about JSR Micro, Inc. Expands JSR Life Sciences Business with MBL International, Appoints New CEO

JSR Corporation Establishes JSR Life Sciences Division, Names North American Leader

The JSR Corporation announced today the formation and establishment of its Life Sciences Division, JSR Life Sciences (JLS). This newly formed JLS has been established as a business unit for Tokyo-based parent company JSR Corporation, a company with more than 50 years of success in material and polymer chemistries including marketing latex and magnetic beads to life sciences and diagnostic companies worldwide. Eric R.

Read more about JSR Corporation Establishes JSR Life Sciences Division, Names North American Leader